



SNS COLLEGE OF ALLIED HEALTH SCIENCE
SNS Kalvi Nagar, Coimbatore - 35
Affiliated to Dr MGR Medical University, Chennai



DEPARTMENT OF OPERATION THEATRE AND ANAESTHESIA TECHNOLOGY - II YEAR

COURSE NAME: PHARMACOLOGY

TOPIC - ANTIARRHYTHMICS

MRS.GAYATHIRI.K
Lecturer






Introduction to Antiarrhythmics



- **Definition:** Drugs that prevent or treat cardiac arrhythmias by modifying heart electrical activity.
- **Purpose:** Restore normal rhythm, prevent complications (e.g., thromboembolism, sudden cardiac death).
- **Types of Arrhythmias:**
 - Supraventricular
(e.g., atrial fibrillation, Flutter)
 - Ventricular (e.g., ventricular tachycardia, fibrillation)

Atrial flutter

250 - 350 bpm





Classification of Antiarrhythmic Drugs



Vaughan-Williams Classification:

- **Class I:** Sodium channel blockers
 - Ia: Quinidine, Procainamide
 - Ib: Lidocaine, Mexiletine
 - Ic: Flecainide, Propafenone
- **Class II:** Beta-blockers (e.g., Propranolol, Metoprolol)
- **Class III:** Potassium channel blockers (e.g., Amiodarone, Sotalol)
- **Class IV:** Calcium channel blockers (e.g., Verapamil, Diltiazem)
- **Others:** Adenosine, Digoxin



Class Ia - Quinidine



- **Definition:** Sodium channel blocker with moderate blockade.
- **Mechanism of Action:** Blocks Na^+ channels, slows phase 0 depolarization; prolongs APD via K^+ channel block.
- **Pharmacodynamics:** Prolongs QT interval, reduces conduction velocity.
- **Pharmacokinetics:**
 - **Absorption:** Oral
 - **Metabolism:** Hepatic.
 - **Excretion:** Renal
 - **Dosage:** 200-400 mg every 6 hours (oral).
- **Onset/Duration:** 1-2 hours/6-8 hours.
- **Interactions:** Increases digoxin levels; QT prolongation with erythromycin.
- **Side Effects:** Cinchonism, hypotension, proarrhythmia.



Class Ia - Procainamide



- **Definition:** Sodium channel blocker with intermediate kinetics.
- **Mechanism of Action:** Blocks Na^+ channels, slows conduction; prolongs APD via K^+ channel effects.
- **Pharmacodynamics:** Prolongs QT interval, moderate conduction slowing.
- **Pharmacokinetics:**
 - **Absorption:** Oral, IV available.
 - **Metabolism:** Hepatic
 - **Excretion:** Renal
 - **Dosage:** 500-1000 mg every 4-6 hours (oral); 20-50 mg/min IV.
- **Onset/Duration:** 30 min (oral), immediate (IV)/3-4 hours.
- **Interactions:** Cimetidine, amiodarone increase levels.
- **Side Effects:** Lupus-like syndrome, agranulocytosis.



Class Ib - Lidocaine



Class: Antiarrhythmic (Class IB), local anesthetic

Definition: Blocks sodium channels to stabilize cardiac membranes and provide local anesthesia.

Pharmacodynamics: Decreases automaticity and conduction velocity in cardiac tissue.

Pharmacokinetics:

Absorption: IV, IM, topical; rapid onset.

Distribution: Widely distributed.

Metabolism: Hepatic.

Excretion: Renal

Mechanism of Action: Blocks voltage-gated sodium channels.

Adverse Effects: CNS toxicity (seizures, confusion), cardiovascular depression, hypersensitivity.

Uses: Ventricular arrhythmias, local anesthesia.

Mode of Administration: IV, IM, topical.

Dilution: 1–2% solution, may dilute in NS for IV infusion.

Dosage: 1–1.5 mg/kg IV bolus, followed by 1–4 mg/min infusion.



Class Ic - Flecainide



- **Definition:** Potent sodium channel blocker.
- **Mechanism of Action:** Strongly blocks Na^+ channels, slows phase 0 depolarization; no APD change.
- **Pharmacodynamics:** Prolongs PR, QRS intervals, potent conduction slowing.
- **Pharmacokinetics:**
 - **Absorption:** Oral
 - **Metabolism:** Hepatic
 - **Excretion:** Renal
 - **Dosage:** 50-150 mg every 12 hours (oral).
- **Onset/Duration:** 1-2 hours/12-24 hours.
- **Interactions:** CYP2D6 inhibitors (e.g., fluoxetine) increase levels.
- **Side Effects:** Proarrhythmia, heart failure exacerbation.



Class III - Amiodarone



Class: Antiarrhythmic (Class III)

Definition: Treats tachy arrhythmias by prolonging cardiac repolarization.

Pharmacodynamics: Prolongs action potential duration and refractory period.

Pharmacokinetics:

Absorption: Oral, IV.

Metabolism: Hepatic.

Excretion: Bile, urine

Mechanism of Action: Blocks potassium channels, prolonging action potential.

Adverse Effects: Pulmonary toxicity, thyroid dysfunction, photosensitivity, corneal micro deposits, QT prolongation.

Uses: Ventricular and supraventricular arrhythmias.

Mode of Administration: IV, oral.

Dilution: 150 mg in 100 mL D5W for IV.

Dosage: 150 mg IV over 10 minutes, then 1 mg/min for 6 hours, 0.5 mg/min for 18 hours; oral 200–400 mg daily.



Class III - Sotalol



- **Definition:** Potassium channel blocker with beta-blocking properties.
- **Mechanism of Action:** Blocks K^+ channels, prolongs APD; non-selective beta-blockade.
- **Pharmacodynamics:** Prolongs QT interval, slows heart rate.
- **Pharmacokinetics:**
 - **Absorption:** Oral.
 - **Metabolism:** Minimal hepatic metabolism.
 - **Excretion:** Renal.
- **Dosage:** 80-160 mg twice daily (oral).
- **Onset/Duration:** 1-2 hours/12-24 hours.
- **Interactions:** QT-prolonging drugs increase torsades risk.
- **Side Effects:** Torsades de pointes, bradycardia.



Other - Adenosine



- **Definition:** Purinergic receptor agonist.
- **Mechanism of Action:** Activates A1 receptors, slows AV node conduction, causes transient AV block.
- **Pharmacodynamics:** Rapidly terminates supraventricular tachycardias.
- **Pharmacokinetics:**
 - **Absorption:** IV only.
 - **Metabolism:** Degraded by adenosine deaminase.
 - **Excretion:** Renal (metabolites), half-life <10 seconds.
- **Dosage:** 6 mg IV bolus, then 12 mg if needed.
- **Onset/Duration:** <30 sec/10-20 sec.
- **Interactions:** Dipyridamole enhances effect; caffeine antagonizes.
- **Side Effects:** Flushing, dyspnea, chest pain.



Other - Digoxin



- **Definition:** Cardiac glycoside for rate control.
- **Mechanism of Action:** Inhibits Na^+/K^+ ATPase, increases vagal tone, slows AV conduction.
- **Pharmacodynamics:** Slows heart rate in atrial fibrillation, no QT effect.
- **Pharmacokinetics:**
 - **Absorption:** Oral.
 - **Metabolism:** Minimal hepatic.
 - **Excretion:** Renal
 - **Dosage:** 0.5-1 mg (loading), 0.125-0.25 mg/day.
- **Onset/Duration:** 1-2 hours (oral), 5-30 min (IV)/2-3 days.
- **Interactions:** Amiodarone, verapamil increase levels.
- **Side Effects:** Nausea, arrhythmias, visual disturbances



THANK YOU